BRIEF published on 10/21/2024 at 20:05, 1 year 7 months ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 7 months ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 1 year 9 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 9 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 1 year 10 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
PRESS RELEASE published on 07/01/2024 at 09:22, 1 year 10 months ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 1 year 11 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
PRESS RELEASE published on 06/27/2024 at 19:22, 1 year 11 months ago Inside Information / Other news releases ABIONYX Pharma announces unanimous approval of all resolutions at its Combined General Meeting. Shareholders renew mandates and approve buyback program Shareholders Buyback Program Renewal Combined General Meeting ABIONYX Pharma
BRIEF published on 06/19/2024 at 21:20, 1 year 11 months ago ABIONYX announces a capital increase without preferential subscription rights Biotechnology Actions United States Increase In Capital Sepsis
PRESS RELEASE published on 06/19/2024 at 21:15, 1 year 11 months ago Inside Information / Other news releases ABIONYX announces capital increase of c.€3.4 million with share issuance and warrants, strengthening financial position for Sepsis and US development, supported by ORSAY 53 investment company Capital Increase Share Issuance ABIONYX Sepsis Development ORSAY 53
Published on 06/01/2026 at 08:00, 29 minutes ago Grande Portage Resources Advances Ongoing Project Studies and Fieldwork to Support New Amalga Gold Project Development
Published on 05/30/2026 at 04:00, 2 days 4 hours ago Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform
Published on 05/30/2026 at 02:40, 2 days 5 hours ago BEACN Announces Financial Results for the First Quarter of 2026 and Update on Loan
Published on 05/30/2026 at 01:30, 2 days 6 hours ago Core Critical Approved for Listing on OTCQB(R) Venture Market
Published on 05/30/2026 at 00:31, 2 days 7 hours ago Gold Basin Resources Provides Updates on Arrangement with CANEX
Published on 06/01/2026 at 08:05, 24 minutes ago Nota AI Works with NVIDIA to Expand Video AI Agent Market… Deployment of VSS-based NVA Spreads
Published on 06/01/2026 at 08:00, 28 minutes ago Unitree Announces H2 Plus, an NVIDIA Isaac GR00T Reference Humanoid Robot for Academic Research
Published on 06/01/2026 at 08:00, 29 minutes ago Celia Pelaz to become CEO “Defence & New Space” at Schaeffler
Published on 06/01/2026 at 08:00, 29 minutes ago EverYield AG: Subscription Period for 9% Infrastructure Bond 2026/2032 Has Started
Published on 06/01/2026 at 07:30, 59 minutes ago Leclanché announces filing of request to extend the publication deadline for the 2025 Annual Report and the temporary suspension of trading of its registered shares on SIX Swiss Exchange as of 1 June
Published on 06/01/2026 at 08:01, 28 minutes ago Saint-Gobain divests HKO, a high-temperature industrial insulation textile business
Published on 06/01/2026 at 06:59, 1 hour 30 minutes ago OPmobility and Yanfeng finalize the strengthening of their Chinese joint venture YFPO
Published on 05/29/2026 at 22:00, 2 days 10 hours ago Information on the Annual Financial Statements 2025
Published on 05/29/2026 at 18:00, 2 days 14 hours ago Recticel Group acquires Isopanel NV to deliver integrated solutions in the cold storage panels market
